This ADC product is composed of an anti-HER2 antibody (Trastuzumab) conjuagated via a CC linker to MMAD (Trastuzumab-CC-MMAD). It has demonstrated a response in breast, ovarian and lung cancer treatment by a MOA (Mechanism of Action) of Depolymerize Microtubules.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
NABG-059 | Recombinant Anti-Human ERBB2 VHH Single Domain Antibody | IHC, FC, CA, FuncS | Llama VHH |
PNBL-066 | Recombinant Anti-HER2 VHH Single Domain Antibody (PNBL-066) | SPR | Llama VHH |
PNBL-067 | Recombinant Anti-HER2 VHH Single Domain Antibody (PNBL-067) | SPR | Llama VHH |
PNBL-069 | Recombinant Anti-HER2 VHH Single Domain Antibody (PNBL-069) | ELISA | Llama VHH |
HPAB-0725-YJ-VHH | Camelid Anti-ERBB2 Recombinant Single Domain Antibody (HPAB-0725-YJ-VHH) | ELISA | Camelid VHH |
There are currently no Customer reviews or questions for ADC-126LCT. Click the button above to contact us or submit your feedback about this product.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.